Orthocell Receives New Patent For Celgro Platform Technology

Published: Sep 21, 2017

• Australian divisional patent granted for CelGro soft tissue reconstruction platform

• Patent covers the method of manufacture of novel bio-scaffolds and as an aid in the surgical repair of soft tissue injuries

• CelGro patents have been previously granted in the US, China, Canada, Singapore, Australia and New Zealand

Perth, Australia; 21st September 2017: Regenerative medicine company Orthocell Limited has today announced it has been granted a further Australian patent for its CelGro collagen medical device platform for soft tissue regeneration and repair applications. The patent entitled “Method for Producing a Collagen Membrane and Uses Thereof” provides additional important intellectual property to protect the CelGro product platform and expires on 12 June 2032.

CelGro is manufactured by Orthocell at its quality controlled (GMP) facility in WA, using the Company’s proprietary SMRTTM tissue engineering process, developed in conjunction with Professor Minghao Zheng and the University of Western Australia. CelGro is a customisable, fit for purpose collagen medical device with numerous competitive advantages over existing synthetic and biologic tissue repair devices, particularly in the areas of cell compatibility, tensile strength and the promotion of quality tissue in growth and repair.

CelGro has been shown to improve tissue in-growth and repair in clinical studies using the collagen medical device to augment repair of the rotator cuff tendon within the shoulder, to guide bone regeneration within the jaw and to assist in the rejoining of severed, or damaged peripheral nerves.

“This is an important addition to our current Australian and global IP portfolio and further strengthens our IP position. This comes at a perfect time for the company as we move our products through the registration processes in Australia and internationally,” Orthocell Managing Director Paul Anderson said.

The company believes CelGro represents a breakthrough in soft tissue reconstruction and offers significant commercial potential in its existing addressable markets of bone, tendon, nerve and cartilage as well as much wider applications in general surgical and soft tissue reconstructive applications. The global orthopaedic soft tissue repair market was worth approximately $US7 billion in 2013 and is expected to be worth more than $US10 billion by 2020.

For more information, please contact:

General enquiries
Paul Anderson
Orthocell Limited, Managing Director
P: +61 8 9360 2888
E: paulanderson@orthocell.com.au

Investor and Media enquiries
Ben Walsh
WE Buchan
P: + 61 411 520 012
E: bwalsh@buchanwe.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of tendon, cartilage and soft tissue injuries. Orthocell’s portfolio of products include TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is Celgro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter @Orthocellltd and Linkedin www.linkedin.com/company/orthocell-ltd

Back to news